Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking ‘the big next step’ after AlphaFold 3

Andrew Dunn

Senior Biopharma Correspondent

A Roivant Sciences spinout says it has made the first AI model, to its knowledge, that simultaneously predicts biomolecule structures while generating new molecules. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking ‘the big next step’ after AlphaFold 3

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

Johnson & Johnson earmarks $55B to boost US capacity

Updated: FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBio

Novo Nordisk says new early R&D structure will ‘future-proof’ its business

Akeso shares new data for bispecific in cervical cancer; Pulmatrix to divest assets

Ex­clu­sive: Roivant-backed Van­tAI de­buts AI mod­el Neo-1, tak­ing ‘the big next step’ af­ter Al­phaFold 3

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

Bridge­Bio, Ed­i­tas fi­nance chiefs de­part; For­mer FDA No. 2 joins Re­cur­sion's board

As­traZeneca broad­ens pres­ence in Chi­na, promis­ing $8B+ to Har­bour and Syneron

John­son & John­son ear­marks $55B to boost US ca­pac­i­ty

Up­dat­ed: FDA ap­proves Al­ny­lam’s Amvut­tra in AT­TR-CM, kick­ing off com­pe­ti­tion with Pfiz­er, Bridge­Bio

No­vo Nordisk says new ear­ly R&D struc­ture will ‘fu­ture-proof’ its busi­ness

Ake­so shares new da­ta for bis­pe­cif­ic in cer­vi­cal can­cer; Pul­ma­trix to di­vest as­sets

Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking ‘the big next step’ after AlphaFold 3

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

Johnson & Johnson earmarks $55B to boost US capacity

Updated: FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBio

Novo Nordisk says new early R&D structure will ‘future-proof’ its business

Akeso shares new data for bispecific in cervical cancer; Pulmatrix to divest assets